Platelets is converting to Open Access
Platelets will convert to an Open Access publishing model starting from June 28, 2022. All manuscripts received after this date will go through the Open Access submission portal, and Authors (or their institutions or funders) who submit their manuscript after this date will need to pay the Article Publishing Charge (APC) associated with the article type if and when their paper is accepted.
The journal focuses on rapid peer review, innovative and novel research, whilst encouraging submissions from as diverse a community as possible. The editorial board will be refreshed as several editors have served their term and the journal will expand its scope and ambition to ensure leading researchers from around the globe direct high quality articles with broad reach and strong impact.
As of 1st January 2023, the journal will have new Editors-in-Chief, Prof Liz Gardiner (Canberra, Australia) and Dr Will Parker (Sheffield, UK). Prof Gardiner was a recipient of an ISTH Esteemed Career Award in 2020. Under their combined stewardship of discovery and clinical research, the journal will continue its focus on publishing leading global research from all areas of platelet research and will continue the special review series, gene of the issue and methods articles.
The conversion to Open Access ensures that the research published in Platelets will be disseminated internationally with no barriers to access. This, combined with the market-leading web platform provided by Taylor & Francis, our innovative communications strategies, and a dedicated Platelets communications account, will mean that all authors who chose to publish in Platelets will reach the widest possible audience. We welcome questions on new manuscripts and future strategy.
As of 1st January 2023, the journal will have new Editors-in-Chief, Prof Liz Gardiner (Canberra, Australia) and Dr Will Parker (Sheffield, UK). The current editors are Steve Watson and Paul Harrison.
Dr William Parker is National Institute of Health & Care Research Clinical Lecturer in Cardiology at the University of Sheffield, UK. He qualified in Medicine and Pharmacology from the University of Cambridge before completing Foundation and Core Medical Training in his home city of Sheffield. He completed six years as a research fellow under the supervision of Professor Rob Storey at the University of Sheffield, training in laboratory techniques and clinical trial design relating to antiplatelet pharmacology. This included a 3-year British Heart Foundation Clinical Training Research Fellowship leading to the award of a PhD. He was appointed Clinical Lecturer in January 2022 and has been a Principal Editor of Platelets since January 2021.
His research interests and publications span the field of atherothrombosis but center on the dose-dependent effects of aspirin on the thrombotic and inflammatory responses. This includes the ongoing ‘WILLOW’ programme of clinical drug trials seeking to explore and optimize combination antithrombotic regimens for aspirin-treated patients with high-risk coronary syndromes. Distinctions have included a high commendation from the International Aspirin Foundation in 2021 and ranking as the top candidate in the UK during cardiology clinical training applications.
Professor Elizabeth Gardiner is the Deputy Director of the John Curtin School of Medical Research at the Australian National University, Canberra, Australia. She received her PhD in Biochemistry from Monash University (1994) and completed a postdoctoral fellowship supported by the American Heart Association at the Cleveland Clinic Foundation, Cleveland OH USA. She is Scientific Director of the National Platelet Referral and Research Centreat ANU and The Canberra Hospital. She has published 168 peer-reviewed research papers, commentaries and reviews in the area of platelet biochemistry and platelet receptor function, particularly relevant to both thrombosis and bleeding in patients. She identified a novel mechanism for shedding of vascular receptors triggered by shear stress, enabling new capabilities in diagnostic and therapeutic reagent development.
She is a Trustee of the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ), Senior Associate Editor of Arteriosclerosis, Thrombosis and Vascular Biology, and on the Editorial Board of Blood. She is Treasurer of the National Association of Research Fellows (NARF). She was 2021 Chair of the American Society of Hematology (ASH) Scientific Committee on Platelets and Megakaryocytes and co-Chair of the International Society for Thrombosis and Haemostasis Biorheology Scientific Subcommittee. She is on the ISTH Membership Committee and the ISTH Basic Science Taskforce.
Why publish open access?
Increase the visibility and readership of your research by publishing in a fully open access journal.
Make an impact beyond the academy by making your article accessible to anyone, anywhere (including readers in industry and even policy-makers).
Freely share your work with no restrictions or paywall.
Retain ownership of your research through our unrestrictive publishing agreements.
Discounts and waivers for researchers in developing countries are available. The journal will also consider requests for discretionary APC waivers. Find out if your institution or country has an open access agreement to publish with us.